What Can I Realistically Expect from Lu-177 DOTATATE for a Metastatic Neuroendocrine Tumor — How Do Doctors Measure Whether It Is Working?

Starting with the right question

When you are living with a metastatic neuroendocrine tumor (NET), one of the hardest things is not knowing what to expect. You may have heard about Lu-177 DOTATATE — also called peptide receptor radionuclide therapy, or PRRT — and you want to know: will it work for me? And how will anyone know if it is?

This article answers those two questions as clearly as the evidence allows. It does not promise cures. It walks you through what clinical trials have shown, the realistic range of results patients may experience, and the tools your care team uses to track whether the treatment is helping.

If you want to understand what scans, blood tests, and numbers your doctor is watching — and what "response" really means for a slow-growing but serious cancer — read on.

What Lu-177 DOTATATE is designed to do

Lu-177 DOTATATE is a radioligand made of two parts: a targeting molecule that seeks out somatostatin receptors on NET cells, and a radioactive particle (lutetium-177) that delivers radiation directly to those cells. The goal is to treat the tumor from the inside out, with less damage to healthy tissue than whole-body radiation.

The U.S. FDA approved Lu-177 DOTATATE in January 2018 for adult patients with somatostatin receptor-positive gastroenteropancreatic NETs, including those of the foregut, midgut, and hindgut. The approval was based on data from a phase III study called NETTER-1.

PRRT is generally considered a treatment that may control a NET rather than eliminate it. For most patients, the goal is to slow or stop tumor growth, manage symptoms, preserve quality of life, and extend time before the disease progresses. Some patients do see tumors shrink, but complete disappearance of all disease is rare.

To learn more about eligibility for this therapy, see our guide: What Lab Results and Scans Do I Need Before Starting Lu-177 DOTATATE?

What the biggest clinical trials actually showed

NETTER-1: the trial that led to FDA approval

The NETTER-1 trial is the most cited evidence for Lu-177 DOTATATE in NETs. It enrolled patients with well-differentiated, somatostatin receptor-positive midgut NETs that had progressed on standard somatostatin analogue therapy.

The primary outcome was progression-free survival (PFS) — how long a patient lives without the disease getting worse. At 20 months, 65.2% of patients in the Lu-177 DOTATATE group had not experienced progression, compared to 10.8% in the control group receiving high-dose octreotide alone. That is a large difference.

Median progression-free survival improved from 8.5 months in the control arm to 25 months in the Lu-177 DOTATATE arm — about three times longer before the cancer grew again.

For overall survival, the final NETTER-1 analysis showed a median of 48.0 months in the Lu-177 DOTATATE group versus 36.3 months in the control group. This roughly 12-month difference did not reach statistical significance, but it pointed in a meaningful direction. The trial also found that patients on Lu-177 DOTATATE experienced a clinically and statistically significant delay in the deterioration of health-related quality of life compared to the control group.

NETTER-2: expanding the evidence to higher-grade tumors

NETTER-1 focused on lower-grade midgut NETs. NETTER-2 looked at patients with higher-grade (grade 2 high or grade 3) GEP-NETs.

NETTER-2 was the first phase III randomized trial to test a radioligand therapy as a first-line treatment in any solid tumor. Results presented at the 2024 ASCO Gastrointestinal Cancers Symposium were striking. Lu-177 DOTATATE nearly tripled median progression-free survival — from 8.5 months with high-dose octreotide to 22.8 months — in patients with untreated, high-grade GEP-NETs. The objective response rate (the share of patients whose tumors visibly shrank) rose from 9.3% in the control group to 43.0% with Lu-177 DOTATATE. Researchers described this as "practice-changing."

Together, these two trials tell a consistent story: Lu-177 DOTATATE can significantly delay tumor growth and, for a meaningful share of patients, produce visible tumor shrinkage.

What do "response rates" really mean for you?

"Objective response rate" (ORR) refers to the share of patients whose tumors actually shrank by a measurable amount. In the FDA approval data set of over 360 GEP-NET patients assessed by RECIST criteria, the ORR was 16%, including 3 complete responses, with a median duration of response of 35 months among those who responded.

That number may seem low, but it does not capture patients with stable disease — meaning the cancer stopped growing for a long time without visibly shrinking. Real-world data show much higher disease control rates overall. One Korean cohort of patients with metastatic NETs reported a disease control rate of 82.9% and a median progression-free survival of 28.8 months with Lu-177 DOTATATE.

Stable disease in a slow-growing NET can be a good outcome. It means the cancer is not spreading, symptoms may be controlled, and daily life can continue. For many patients and their doctors, halting progression is the real goal.

How doctors measure whether Lu-177 DOTATATE is working

Your care team will use imaging scans, blood tests, and symptom tracking to decide whether treatment is helping. Here is what each one looks for.

1. Cross-sectional imaging: CT and MRI scans

CT and MRI scans are the standard way to measure whether tumors have grown, shrunk, or stayed the same size. Doctors use a system called RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) to make these measurements consistently. They measure a set of "target lesions" at baseline and again after treatment, tracking any change in total size.

Most centers perform imaging about 3 months after completing all four treatment cycles, though timing may vary. Tumors can sometimes appear temporarily larger on scans shortly after PRRT — called pseudo-progression — even when treatment is working. Your care team will factor this in when reviewing results.

2. Gallium-68 DOTATATE PET/CT scans

A Ga-68 DOTATATE PET/CT scan shows how strongly tumor cells express somatostatin receptors. Before treatment, this scan confirms you are likely to respond to PRRT. After treatment, it can help show whether tumors are still expressing somatostatin receptors — which matters for whether remaining disease can still be targeted.

Research has shown that post-treatment PET/CT and images taken shortly after each Lu-177 infusion tend to track together, giving your team a functional picture of how well the therapy is reaching tumor sites. PET findings after PRRT do not always perfectly predict outcomes, so they are interpreted alongside CT/MRI and blood markers.

3. Blood and urine biomarkers

Your oncologist will monitor several lab values throughout treatment. The most important ones include:

• Chromogranin A (CgA): A protein released by NET cells. Falling CgA levels after treatment often suggest the tumor is responding. Doctors also track Ki-67 (the tumor's proliferation index) as a baseline predictor of how aggressive the cancer is and how likely it is to respond.
• 24-hour urine 5-HIAA: Relevant for carcinoid tumors, this measures a byproduct of serotonin. Falling levels may point to reduced tumor secretion and better symptom control.
• Blood counts: Lu-177 DOTATATE can affect bone marrow function, so your team will monitor white blood cells, red blood cells, and platelets throughout treatment.
• Kidney function tests: Because the kidneys are exposed to radiation during treatment, creatinine and other kidney markers are checked at every cycle.

Research on GEP-NET patients treated with Lu-177 DOTATATE has shown that tumor dosimetry — measuring how much radiation the tumor actually absorbs — can help predict both treatment response and toxicity, allowing your team to adjust your care over time.

4. Symptom and quality-of-life tracking

For patients with functioning NETs — those that actively secrete hormones causing symptoms like diarrhea, flushing, or abdominal pain — symptom relief is itself a meaningful measure of whether treatment is working.

In studies of patients with functioning NETs who were no longer responding to somatostatin analogues alone, 88% experienced a "syndrome response" after Lu-177 DOTATATE — meaning their tumor-related symptoms meaningfully improved. The 2-year overall survival in those who had a syndrome response was around 93.9%, substantially better than non-responders. This suggests that symptom improvement may reflect a deeper biological response to treatment, not just a quality-of-life benefit.

For more on how symptoms tend to change during and after PRRT, see our related article: Will Lu-177 DOTATATE Make My Neuroendocrine Tumor Symptoms Better?

What a realistic range of outcomes looks like

It can help to think about outcomes in three broad categories:

• Response (tumor shrinkage): This occurs in roughly 15–43% of patients depending on tumor grade and prior treatment history. Responses can last for years in some patients.
• Stable disease (no growth): This is the most common outcome. Many patients find their tumors stop progressing for a year or more — sometimes much longer. This is often considered a treatment success in slow-growing NETs.
• Progression: In a smaller share of patients, the cancer continues to grow despite treatment. This is more likely with higher-grade tumors, heavily pretreated disease, or lower somatostatin receptor expression.

One real-world study of 55 patients with well-differentiated NETs treated with Lu-177 DOTATATE showed a median progression-free survival of 34.1 months, with median overall survival not yet reached at the time of analysis. Factors associated with better outcomes include lower-grade disease (Ki-67 below 15%), fewer bone metastases, and good overall performance status.

Lu-177 DOTATATE is not a one-size-fits-all therapy, and outcomes vary. Your care team will use your specific tumor characteristics, scan results, blood work, and overall health to give you a more personalized picture.

If you are wondering what options exist if Lu-177 DOTATATE eventually stops working, our article What Are My Options If Lu-177 DOTATATE Stops Working? covers the evidence on next steps.

One important nuance: tumor shrinkage is not the only sign of success

In many cancers, tumor shrinkage is treated as the gold standard of response. In NETs treated with PRRT, the picture is more complicated. An analysis of NETTER-1 data found that the degree of tumor shrinkage on scans was not strongly linked to how long patients stayed progression-free. A patient whose tumor shrank a little and one whose tumor shrank a lot might have similarly durable disease control.

This matters because stable disease — even without dramatic shrinkage — may be a genuine sign the therapy is working. It also means your oncologist will look at the full picture: scans, symptoms, blood markers, and how you feel.

Questions to ask your care team

Here are some practical questions to consider raising with your oncologist before or during Lu-177 DOTATATE treatment:

• What is my baseline chromogranin A level, and how often will you check it?
• When will I have my first post-treatment scan, and what system will you use to assess my response?
• What would "stable disease" mean for my situation, and how would we know if the therapy stops working?
• Are there features of my tumor — grade, Ki-67, location of metastases — that would make me more or less likely to respond?
• What is the plan if my response is less than expected after the first two cycles?

When to talk to your doctor

Contact your care team promptly if you notice new or worsening symptoms between treatment cycles — such as increased pain, changes in bowel habits, unexplained fatigue, or unusual bruising. These may be unrelated to treatment, but your team needs to know. Also speak with your oncologist before drawing conclusions from a single scan result; response in NETs is best assessed over time and across multiple measures.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.